Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Antoni Ribas(University of California, Los Angeles), Caroline Robert(Institut Gustave Roussy), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Xiaoyun Li(Nanjing University), Robert Iannone(Cornell University), Tara C. Gangadhar(University of Pennsylvania), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 54
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k